ESR1 and breast carcinoma: Following an antibody-based proteomics biomarker discovery strategy using the Human Protein Atlas (HPA) (http://www.proteinatlas.org) [14,15] we recently demonstrated an association between nuclear RBM3 expression in breast cancer and a significantly improved survival, particularly in estrogen receptor (ER) positive tumors [16].